Chiome Bioscience, Inc. engages in the development and sale of antibody drugs through the Autonomous Diversifying Library (ADLib) system. Its operations are carried out through the Drug Discovery and Drug Discovery Support business segments. The Drug Discovery segment develops antibody drug development in disease areas where unmet needs are high, out-license patents and other licenses related to the resulting antibody to pharmaceutical companies. The Drug Discovery Support segment handles antibody production using antibody production technologies to support drug discovery research conducted by research institutes such as pharmaceutical companies, diagnostic drug companies, and universities. The company was founded by Kunihiro Ohta on February 8, 2005 and is headquartered in Tokyo, Japan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company